
Vasc Surg 2019;59. 306.e11-5.

139. De Martino RR, Eldrup-Jorgensen J, Nolan BW, Stone DH,
Adams J, Bertges DJ, et al. Perioperative management with
antiplatelet and statin medication is associated with
reduced mortality following vascular surgery. J Vasc Surg
2014;59:1615-21. 1621.e1.
140. Peeters Weem SM, van Haelst ST, den Ruijter HM, Moll FL,
de Borst GJ. Lack of evidence for dual antiplatelet therapy
after endovascular arterial procedures: a meta-analysis. Eur
J Vasc Endovasc Surg 2016;52:253-62.
141. Cholesterol Treatment Trialists’ (CTT) Collaboration,
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C,
et al. Efﬁcacy and safety of more intensive lowering of LDL
cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
142. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Eiaz R,
Widimsky P, et al. Rivaroxaban with or without aspirin in
patients with stable peripheral or carotid artery disease: an
international,
randomised,
double-blind,
placebocontrolled trial. Lancet 2018;391:219-29.
143. Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM,
Anand SS, et al. Rationale and design for the Vascular
Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral
artery disease (VOYAGER PAD). Am Heart J 2018;199:83-91.
144. Patel MR, Becker RC, Wojdyla DM, Emanuelsson H,
Hiatt WR, Horrow J, et al. Cardiovascular events